23.94
0.75 (3.23%)
| Previous Close | 23.19 |
| Open | 23.25 |
| Volume | 50,122 |
| Avg. Volume (3M) | 1,350,329 |
| Market Cap | 1,780,020,480 |
| Price / Sales | 17.33 |
| Price / Book | 3.58 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2026 |
| Profit Margin | -163.17% |
| Operating Margin (TTM) | -131.93% |
| Diluted EPS (TTM) | -3.04 |
| Quarterly Revenue Growth (YOY) | 104.60% |
| Total Debt/Equity (MRQ) | 34.73% |
| Current Ratio (MRQ) | 5.89 |
| Operating Cash Flow (TTM) | -161.55 M |
| Levered Free Cash Flow (TTM) | -84.53 M |
| Return on Assets (TTM) | -11.42% |
| Return on Equity (TTM) | -34.05% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Xencor, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -1.67 |
Select this tab to load the latest available analysis.
|
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.24% |
| % Held by Institutions | 111.90% |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |